Entries have opened for next year’s UK Prix Galien Awards, widely regarded as the highest accolade for pharmaceutical R&D.
The 2016 awards, which will include a new category for Real-World Evidence alongside the well-established prizes for Innovative Product and Orphan Product, will be held at a ceremony in the House of Commons on September 21.
Prix Galien, established in 1970 in France, and considered as the industry’s equivalent of the Nobel prize, celebrates “outstanding efforts to improve the human condition through the development of novel, high-value medicines”. Prix Galien awards are now granted in 11 countries across Europe and North America, and a presence in emerging markets in Asia and Latin America is expected soon.
The 2016 UK judging panel is once again led by Professor Sir Michael Rawlins, chair of MHRA and ex-chair of NICE (from 1999 to 2014). He will be joined on the panel by other healthcare luminaries, such as Professor Sir Mike Richards, chief inspector of hospitals at the Care Quality Commission and June Raine, chair of the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee.
Previous UK Prix Galien winners include well-known medicines such as Pfizer’s erectile dysfunction blockbuster Viagra (sildenafil) and Roche’s breast cancer therapy Herceptin (trastuzumab). In 2014, the Innovative Product Award was won by Novartis’ meningococcal vaccine Bexsero, while the Orphan Drug Award went to Janssen’s Sirturo (bedaquiline), the first ever vaccine to treat invasive meningococcal disease.
Registration for entries for the 2016 Awards, the UK partner for which is healthcare business intelligence specialists ValueBase, will close on February 29, with final submissions due by April 29. For further details on the entry process visit www.prixgalien.co.uk and download the entry brochure.